AI Article Synopsis
- The case describes a rare instance of ductal carcinoma in situ (DCIS) appearing alongside a phyllodes tumor (PT) in a pre-menopausal woman.
- The patient underwent a wide local excision and oncoplasty, leading to a postoperative finding of borderline PT with high-grade DCIS.
- After treatment with radiotherapy and hormonal therapy, the patient remained recurrence-free for three years, highlighting the importance of multidisciplinary care and careful monitoring in such unique cases.
Article Abstract
The co-existence of breast carcinoma in the form of ductal carcinoma in situ (DCIS) in a case of Phyllodes tumor (PT) is extremely rare. We present a case of a pre-menopausal lady with a large breast lump diagnosed as benign PT on her initial biopsy. Wide local excision and breast conservation with round block oncoplasty were done. A post-operative diagnosis of borderline PT with sclerosing adenosis and high-grade DCIS were made. Adjuvant radiotherapy and hormonal therapy were given, and the patient had no recurrence after three years of follow-up. DCIS in PT is very rare, and hence no standard protocol for treating such cases exists. So proper histopathological diagnosis, treatment with multidisciplinary involvement, and regular follow-up can help us conserve the breast and prevent recurrence in such cases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11498070 | PMC |
| http://dx.doi.org/10.7759/cureus.70012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Divergent response to radio-immunotherapy is defined by intrinsic features of the tumor microenvironment.
J Immunother Cancer
January 2025
Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, USA
Background: Treatment with immunotherapy can elicit varying responses across cancer types, and the mechanistic underpinnings that contribute to response vrsus progression remain poorly understood. However, to date there are few preclinical models that accurately represent these disparate disease scenarios.
Methods: Using combinatorial radio-immunotherapy consisting of PD-1 blockade, IL2Rβγ biased signaling, and OX40 agonism we were able to generate preclinical tumor models with conflicting responses, where head and neck squamous cell carcinoma (HNSCC) models respond and pancreatic ductal adenocarcinoma (PDAC) progresses.
Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic mice.
J Exp Clin Cancer Res
January 2025
Department of Medical and Surgical Sciences, Medical Oncology , Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Rome, Italy.
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and deadly type of cancer, with an extremely low five-year overall survival rate. To date, current treatment options primarily involve various chemotherapies, which often prove ineffective and are associated with substantial toxicity. Furthermore, immunotherapies utilizing checkpoint inhibitors have shown limited efficacy in this context, highlighting an urgent need for novel therapeutic strategies.
View Article and Find Full Text PDFDifferent Cytotoxic Effects of Cisplatin on Pancreatic Ductal Adenocarcinoma Cell Lines.
Int J Mol Sci
December 2024
Dipartimento di Scienze e Tecnologie Biologiche e Ambientali (Di.S.Te.B.A.), Università del Salento, Via Provinciale per Monteroni, 73100 Lecce, Italy.
This study examined the response to cisplatin in BxPC-3, Mia-Paca-2, PANC-1, and YAPC pancreatic cancer lines with different genotypic and phenotypic characteristics, and the mechanisms associated with their resistance. BxPC-3 and MIA-PaCa-2 cell lines were the most sensitive to cisplatin, while YAPC and PANC-1 were more resistant. Consistently, in cisplatin-treated BxPC-3 cells, the cleavage patterns of pro-caspase-9, -7, -3, and PARP-1 demonstrated that they were more sensitive than YAPC cells.
View Article and Find Full Text PDFChanges in Pancreatic Cancer Management and Surgical Treatment During the COVID-19 Pandemic.
Medicina (Kaunas)
November 2024
Regional Institute of Gastroenterology and Hepatology "Octavian Fodor", 400394 Cluj-Napoca, Romania.
: This study evaluated the impact of the COVID-19 pandemic on the surgical management of pancreatic ductal adenocarcinoma (PDAC) at a tertiary care hospital in Romania. The objective was to compare surgical volumes, tumor characteristics, and patient outcomes across three periods: pre-COVID, pandemic, and post-COVID. : A retrospective analysis of 622 PDAC patients who underwent surgery between February 2018 and February 2024 was conducted.
View Article and Find Full Text PDFUpregulation of Differentiates Intrahepatic Cholangiocarcinoma from Hepatocellular Carcinoma and Both Colorectal and Pancreatic Adenocarcinoma Liver Metastases.
Genes (Basel)
November 2024
Institute of Pathology, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.
Background: Altered gene expression in cancers holds great potential to improve the diagnostics and differentiation of primary and metastatic liver cancers. In this study, the expression of the protein-coding genes ring finger protein 135 (), ephrin-B2 (), ring finger protein 125 (), homeobox-C 4 (), actin-binding LIM protein 1 () and oncostatin M receptor () and the long non-coding RNAs (lncRNA) prospero homeobox 1 antisense RNA 1 () and leukemia inhibitory factor receptor antisense RNA 1 () was investigated in hepatocellular carcinoma, cholangiocarcinoma, colorectal liver metastases and pancreatic ductal adenocarcinoma liver metastases.
Methods: This study included 149 formalin-fixed, paraffin-embedded samples from 80 patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!